Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Qnexa May Get Staged Launch After No Vote From Advisory Committee

This article was originally published in The Pink Sheet Daily

Executive Summary

Safety concerns and a large market potential for Vivus's obesity drug combine to produce an advisory panel recommendation that leaves FDA "a little surprised."

You may also be interested in...



Qnexa’s Second Advisory Committee Review: Smaller Indication, Still Big Safety Questions

Vivus’ weight loss drug Qnexa (phentermine/topiramate) will go before the Endocrinologic and Metabolic Drugs Advisory Committee again on Feb. 22 for an indication that excludes women of childbearing age. And despite additional safety data, cardiovascular concerns look to remain a major issue for the resubmitted application.

Vivus Resubmits Qnexa, But Limits Its Market Opportunity

The biotech once again submits its application to FDA for its obesity drug, but the upside potential is drastically cut.

Vivus Resubmits Qnexa, But Limits Its Market Opportunity

The biotech once again submits its application to FDA for its obesity drug, but the upside potential is drastically cut.

Related Content

Topics

UsernamePublicRestriction

Register

PS070902

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel